CTRI/2020/06/026209尚未招募2 期
A Randomized, Parallel Group, Open Label, Standard Controlled Clinical Study to Evaluate Efficacy and Safety of Unani Formulations (Oral and Topical) in Management of Bahaq (Pityriasis Versicolor) - RCTPV
ational Research Institute of Unani Medicine for Skin Disorders Hyderabad0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Participants of any sex aged 19-60 years
- •Participant having any of the sign and symptoms of Bahaq
- •Hypopigmented macule
- •Hyperpigmented macule
- •Pruritus on the lesion
- •Scaling / Desquamation and
- •Presence of Malassezia furfurin the scrapings of the lesion
排除标准
- •Participant with serious co-morbid medical condition and other fungal infection
- •Participant who had received any systemic or topical antimycotic therapy within month of start of study
- •Pregnant or Lactating Women
- •Significant Pulmonary/Cardiovascular/Hepato-renal Dysfunction
- •Known cases of Immunocompromised states (HIV/ AIDS, etc.)/ Malignancies
- •Participant not willing to attend treatment schedule regularly
研究者
相似试验
尚未招募
2 期
Evaluating Efficacy of Unani Formulation in TineaCTRI/2021/08/036043ational Research Institute of Unani Medicine for Skin Disorders
尚未招募
2 期
unani treatment of Kathra al-Bawl (Overactive Bladder) with Jawarish Kundur and OxybutyniCTRI/2023/03/050407Central Council for research in Unani Medicine
进行中（未招募）
不适用
A Randomized, Open Label, Parallel Group, International, Multicenter, Phase III Study of Oral ZD1839 (IRESSA®) Versus Intravenous Docetaxel (TAXOTERE®) in Patients With Locally Advanced or Metastatic Recurrent Non Small Cell Lung Cancer who have Previously Received Platinum Based Chemotherapy - INTERESTocally Advanced or Metastatic Recurrent Non-Small Cell Lung CancerEUCTR2004-002943-28-LVAstraZeneca AB1,440
进行中（未招募）
不适用
An Open Label, Randomised, Parallel Group, Multicentre Study toCompare ZOLADEX™ 10.8 mg Given Every 12 Weeks with ZOLADEX3.6 mg Given Every 4 Weeks in Pre-menopausal Women with OestrogenReceptor Positive Advanced Breast CancerEUCTR2005-004001-29-CZAstraZeneca AB260
未知
3 期
An Open Label, Randomised, Parallel Group, Multicentre Study to Compare ZOLADEX 10.8 mg Given Every 12 Weeks With ZOLADEX 3.6 mg Given Every 4 Weeks in Pre-menopausal Women With Oestrogen Receptor Positive Advanced Breast CancerBreast CancerJPRN-jRCT2080221070AstraZeneca